Predict your next investment

Venture Capital
greenskycapital.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

1

Funds

5

About GreenSky Capital

GreenSky Capital is a Toronto-based firm that manages a series of venture capital funds that invest in early-stage, B2B-focused Canadian start-ups. GreenSky looks for long-term partnerships with high-growth potential companies and dedicated entrepreneurs and focuses on companies with complex intellectual property-seeking support scaling their businesses. Its partners are successful entrepreneurs with multiple exits that bring a unique combination of experience in technology, law, and finance into a real-world context.

GreenSky Capital Headquarter Location

6 Adelaide St E Suite 500

Toronto, Ontario, M5J 1T1,

Canada

416-585-7850

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GreenSky Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find GreenSky Capital in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Research containing GreenSky Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned GreenSky Capital in 1 CB Insights research brief, most recently on Sep 3, 2020.

Latest GreenSky Capital News

PHENOTIPS SECURES $2.5 MILLION CAD TO EXPAND REACH OF MEDICAL GENETICS SOFTWARE

Sep 22, 2021

UTEST startup  PhenoTips  has raised $2.5 million CAD in its first round of venture financing, as it looks to help healthcare providers prepare “for the imminent mainstreaming of genomic medicine.” The all-equity seed round, which closed earlier this month, was led by Toronto-based GreenSky Capital’s GreenSky Accelerator Fund IV. The round also saw participation from the Toronto Innovation Acceleration Partners, Calgary-based Thin Air Labs, Toronto’s Yorkville Partners, and a group of undisclosed angel investors, including members of the GreenSky President’s Club. Since its launch, PhenoTips has grown into an enterprise software-as-a-service firm that currently serves over 200,000 patients. PhenoTips, which was  formerly known as Gene42 , was founded in 2014 as part of a University of Toronto and SickKids research project. The startup which touts itself as “the world’s first Genomic Health Record,” offers software for genomic medicine workflows that enables healthcare providers and researchers to ensure clinical data is complete, standardized, shareable, and interoperable. After establishing a presence in Canada, the United States, the United Kingdom, and Europe, PhenoTips aims to use the fresh capital to bring its offering to more hospitals and health systems in those markets. The startup also sees an opportunity in expanding to serve a wider set of specialists within the hospitals and healthcare providers it works with. PhenoTips’ software allows specialists to record and use genetic information to help diagnose patients and advance genetics research. The startup aims to increase the use and access to genetic sequencing. PhenoTips has positioned itself to capitalize on what CEO Orion Buske calls the “incredible shift in focus from research to clinical adoption” of genomic medicine. Buske told BetaKit this development has been driven by maturity of knowledge and a decrease in cost. “It’s making more and more financial, business, health, economic sense to reimburse for genome sequencing, or exome sequencing, and to … use that as a tool earlier and earlier in the healthcare journey, in the diagnostic journey of the patient,” said Buske. Genomic sequencing has a variety of potential medical applications, ranging from research to the diagnosis of diseases. Over the past 20 years, the cost of sequencing a human genome has dropped significantly. According to the National Human Genome Research Institute, “technological improvements and automation have increased speed and lowered costs to the point where individual genes can be sequenced routinely, and some labs can sequence well over 100,000 billion bases per year, and an entire genome can be sequenced for just a few thousand dollars.” PhenoTips was born out of a joint research project by University of Toronto computer scientists and SickKids-based geneticists, who set out to build a database connecting physical descriptions (phenotypes) to genetic characteristics (genotypes). However, they soon discovered that mining this data from existing medical records “would be impossible” due to missing, inconsistent, or ambiguous information. To address this issue, the project research team developed PhenoTips, a software tool that codes patient records using human phenotype ontology (HPO), a standardized, hierarchical language for describing phenotypes. In 2018, under Buske’s leadership, PhenoTips was spun out into a standalone company called Gene42, following interest from potential clients. “PhenoTips started eight years ago as an academic research project to help specialists record more standardized patient data at a nearby hospital’s genetics clinic,” said Buske. “Today, we help specialists around the world not just record, but also use this information to help diagnose patients and advance genetics research.” Buske, who has a PhD in computer science from the University of Toronto and previously worked on the initial research project, went to work translating PhenoTips from a research project into a clinical tool. Last year, the startup participated in the Creative Destruction Lab and rebranded to PhenoTips. Since its launch, PhenoTips has grown into an enterprise software-as-a-service firm that currently serves over 200,000 patients and hospitals, healthcare providers, and researchers across four countries. “PhenoTips works at the intersection of genetics and precision medicine—two areas that we believe are poised to experience outsized short and long-term growth,” said Greg Stewart, managing partner at GreenSky. “With a best-in-class product and a team composed of some of the key opinion leaders in the space, PhenoTips is positioned to be a major player in the space.” PhenoTips’ customers include Canadian provincial health authorities, UK NHS Trusts, individual hospitals, and genetics companies like Regeneron and Genome Medical. Armed with its seed funding, the company plans to add new hospital, healthcare provider, and research customers. Given that many of PhenoTips’ current customers are genetics departments, the startup is also looking to expand to serve “genetics-adjacent” departments like cardiology, oncology, and neurology within its existing client base. “This is about us basically laying the foundations for scaling up our technology, and scaling up our offering, and expanding that offering in anticipation of this expansion of genetics into other specialties,” said Buske. To support these goals, PhenoTips plans to use the fresh capital to double the size of its 12-person team, as it looks to hire on the technical and project management side, as well as in sales roles. Source: Betakit – https://betakit.com/phenotips-secures-2-5-million-cad-to-expand-reach-of-medical-genetics-software/

GreenSky Capital Investments

25 Investments

GreenSky Capital has made 25 investments. Their latest investment was in PhenoTips as part of their Seed VC on September 9, 2021.

CBI Logo

GreenSky Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/21/2021

Seed VC

PhenoTips

$1.95M

Yes

9

6/3/2021

Series A

Anessa

Yes

3

4/28/2021

Seed VC

Pulse Industrial

$1.9M

Yes

1

9/2/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/24/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/21/2021

6/3/2021

4/28/2021

9/2/2020

6/24/2020

Round

Seed VC

Series A

Seed VC

Series A

Series B

Company

PhenoTips

Anessa

Pulse Industrial

Subscribe to see more

Subscribe to see more

Amount

$1.95M

$1.9M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

3

1

10

10

GreenSky Capital Portfolio Exits

1 Portfolio Exit

GreenSky Capital has 1 portfolio exit. Their latest portfolio exit was Rank Software on September 08, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/8/2020

Acquired

1

Date

9/8/2020

Exit

Acquired

Companies

Valuation

Acquirer

Sources

1

GreenSky Capital Fund History

5 Fund Histories

GreenSky Capital has 5 funds, including GreenSky Accelerator Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/4/2021

GreenSky Accelerator Fund IV

$12.46M

2

1/20/2020

GreenSky Accelerator Fund III, LP

Subscribe to see more

$99M

10

7/26/2017

GreenSky Accelerator Fund II

Subscribe to see more

$99M

10

7/8/2015

GreenSky Accelerator Fund I

Subscribe to see more

$99M

10

7/8/2015

The GreenSky Accelerator Fund I LP

Subscribe to see more

$99M

10

Closing Date

6/4/2021

1/20/2020

7/26/2017

7/8/2015

7/8/2015

Fund

GreenSky Accelerator Fund IV

GreenSky Accelerator Fund III, LP

GreenSky Accelerator Fund II

GreenSky Accelerator Fund I

The GreenSky Accelerator Fund I LP

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$12.46M

$99M

$99M

$99M

$99M

Sources

2

10

10

10

10

GreenSky Capital Team

2 Team Members

GreenSky Capital has 2 team members, including current Chief Compliance Officer, James Brink.

Name

Work History

Title

Status

James Brink

Chief Compliance Officer

Current

Greg Stewart

Managing Partner

Current

Name

James Brink

Greg Stewart

Work History

Title

Chief Compliance Officer

Managing Partner

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.